ODT in BE study [Design Issues]

posted by Farmacevt – North Macedonia, 2022-01-18 17:01 (1620 d 14:03 ago) – Posting: # 22732
Views: 4,457

Dears,

I would appreciate if you can share your opinion regarding this particular case:

IF you develop generic orodispersible tablet (ODT) and the reference formulation is immediate release tablet (obviously it can be administrate only with water) is it enough to perform two way cross-over study where the ODT will be administrated without water and the reference tbl. with water, or 3 arm study (ODT administrated in both ways with and without water and the reference with water) should be performed?


Thank you

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
378 visitors (0 registered, 378 guests [including 17 identified bots]).
Forum time: 08:04 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5